Novel Antifibrotic Gets Orphan Drug Status for Idiopathic Pulmonary Fibrosis

The FDA has granted Orphan Drug designation to AGMB-447 for the treatment of idiopathic pulmonary fibrosis.

Related Keywords

,Philippe Wiesel ,Drug Administration ,Orphan Drug ,Chief Medical Officer ,